Literature DB >> 2917588

Exercise haemodynamic effects of beta-blockade and intrinsic sympathomimetic activity.

P A Ades1, E E Wolfel, W R Hiatt, C Fee, R Rolfs, H L Brammell, L D Horwitz.   

Abstract

Beta-adrenergic blockade with intrinsic sympathomimetic activity (ISA) causes less depression of resting and submaximal heart rate (HR) than non-ISA beta-blockers. The effects of these drugs on exercise haemodynamics have not been well studied. We evaluated effects of pindolol, propranolol and placebo during rest and steady-state exercise on cardiac output, oxygen consumption, calf blood flow, HR and blood pressure in 18 healthy subjects. Pindolol 5 mg and propranolol 80 mg given twice daily, reduced maximal exercise HR by 50 and 52 beats.min-1 respectively, confirming similarity of beta 1-blockade. Resting cardiac output was unchanged in all three groups after one week of therapy. Cardiac output, measured during steady-state exercise decreased in the propranolol group (18.3 vs 15.6 l.min-1) with no significant changes in pindolol (15.7 vs 16.01.min-1) or placebo (18.6 vs 17.3 l.min-1). The rise in cardiac output, from rest to exercise, was similarly attenuated by propranolol but not by pindolol or placebo. Exercise stroke volume increased 12% on pindolol (123-140 cc) and decreased 7% on propranolol (143-133 cc). Neither drug had a detrimental effect on exercise calf blood flow compared to placebo. Thus, unlike propranolol, pindolol with ISA, maintains a normal cardiac output during submaximal exercise.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2917588     DOI: 10.1007/BF00561015

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  17 in total

1.  Pindolol: a pharmacokinetic comparison with other beta-adrenoceptor blocking agents.

Authors:  J Meier
Journal:  Acta Med Scand Suppl       Date:  1977

2.  Abnormalities of left ventricular contraction induced by beta adrenergic blockade.

Authors:  R H Helfant; M V Herman
Journal:  Circulation       Date:  1971-05       Impact factor: 29.690

3.  A comparison of the reproducibility and physiologic response to three maximal treadmill exercise protocols.

Authors:  V F Froelicher; H Brammell; G Davis; I Noguera; A Stewart; M C Lancaster
Journal:  Chest       Date:  1974-05       Impact factor: 9.410

4.  Attenuation of exercise conditioning by low dose beta-adrenergic receptor blockade.

Authors:  R C Marsh; W R Hiatt; H L Brammell; L D Horwitz
Journal:  J Am Coll Cardiol       Date:  1983-09       Impact factor: 24.094

5.  How intrinsic sympathomimetic activity modulates the haemodynamic responses to beta-adrenoceptor antagonists. A clue to the nature of their antihypertensive mechanism.

Authors:  A J Man in 't Veld; M A Schalekamp
Journal:  Br J Clin Pharmacol       Date:  1982       Impact factor: 4.335

6.  Effects of propranolol on left ventricular function in normal men.

Authors:  S Port; F R Cobb; R H Jones
Journal:  Circulation       Date:  1980-02       Impact factor: 29.690

7.  Effect of beta blockade and intrinsic sympathomimetic activity on exercise performance.

Authors:  P A Ades; H L Brammell; J H Greenberg; L D Horwitz
Journal:  Am J Cardiol       Date:  1984-12-01       Impact factor: 2.778

8.  Attenuation of exercise conditioning by beta-adrenergic blockade.

Authors:  D L Sable; H L Brammell; M W Sheehan; A S Nies; J Gerber; L D Horwitz
Journal:  Circulation       Date:  1982-04       Impact factor: 29.690

9.  Validation of the CO2 rebreathing method for measuring cardiac output in patients with hypertension or heart failure.

Authors:  J A Franciosa; D O Ragan; S J Rubenstone
Journal:  J Lab Clin Med       Date:  1976-10

10.  Measurement of partial agonist activity of pindolol.

Authors:  S G Carruthers; Y Twum-Barima
Journal:  Clin Pharmacol Ther       Date:  1981-11       Impact factor: 6.875

View more
  1 in total

1.  Acute aerobic exercise reduces 24-h ambulatory blood pressure levels in long-term-treated hypertensive patients.

Authors:  Emmanuel G Ciolac; Guilherme V Guimarães; Veridiana M D'Avila; Luiz A Bortolotto; Egídio L Doria; Edimar A Bocchi
Journal:  Clinics (Sao Paulo)       Date:  2008-12       Impact factor: 2.365

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.